Analyst & Firm | Company | Price | Rating & Price Target | Upside / Downside | Success Rate | Average Return | Action | Date | Article |
---|---|---|---|---|---|---|---|---|---|
Shoals Technologies Group | SELL $5 | ― | -24.10% | Assigned | Shoals Technologies Group Sell Recommendation Amid Patent Litigation Concerns and Margin Pressures | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $65 | ― | 20.50% | Assigned | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $39→$37.25 | ― | 14.20% | Assigned | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $280→$255 | ― | 10.40% | Downgraded | |||||
WalkMe | BUY $19 | ― | -6.50% | Reiterated | WalkMe (WKME) Receives a Buy from JMP Securities | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $38→$25 | ― | 0.80% | Downgraded | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $292 | ― | 2.20% | Assigned | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $2→$1 | ― | 1.70% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $123→$138 | ― | 16.20% | Reiterated | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $228 | ― | 3.60% | Assigned | |||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $40→$37 | ― | 6.50% | Downgraded | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $12 | ― | 7.80% | Assigned | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $50 | ― | 13.60% | Assigned | ||||
Waystar Holding Corp. | BUY $24 | ― | -5.70% | Initiated | Waystar Holding Corp. (WAY) Receives a New Rating from Barclays | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $760 | ― | 1.90% | Initiated | ||||
AbSci | BUY $7 | ― | -14.90% | Initiated | Buy Rating on AbSci: AI/ML Innovation, Strong Partnerships, and Attractive Valuation Present Investment Opportunity | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $34 | ― | 11.40% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $21 | ― | 3.40% | Upgraded | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $211 | ― | 14.80% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $32 | ― | 7.90% | Reiterated | ||||
Baidu | BUY $135 | ― | -24.80% | Assigned | Baidu's Strategic Focus and ROIC Improvement Justify Buy Rating | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $46 | ― | 12.40% | Assigned | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $42 | ― | 12.40% | Assigned | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $220 | ― | 12.40% | Assigned | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $18 | ― | 12.40% | Assigned | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $150 | ― | 12.40% | Assigned | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $90 | ― | 12.40% | Assigned | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $92 | ― | 12.40% | Assigned | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $194 | ― | 12.40% | Assigned | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $18 | ― | 12.40% | Assigned | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $91 | ― | 12.40% | Assigned | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $504 | ― | 12.40% | Assigned | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $45 | ― | 12.40% | Assigned | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $42 | ― | 6.60% | Initiated | |||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $17→$12 | ― | 4.10% | Reiterated | |||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD | ― | 19.00% | Downgraded | |||||
Versus Systems | HOLD $1.5→$2 | ― | -17.00% | Reiterated | Versus Systems: Hold Rating Amidst Management Shift and Restructuring Risks | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $190 | ― | 5.00% | Reiterated | ||||
Abeona Therapeutics | BUY $15 | ― | -1.40% | Initiated | Buy Rating Affirmed for Abeona Therapeutics on Promising pz-cel Therapy for RDEB | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $5 | ― | 4.60% | Upgraded | ||||
Tyra Bioscience | BUY $23 | ― | -16.70% | Reiterated | Buy Rating Affirmed for Tyra Bioscience on TYRA-300's Promising Preclinical Efficacy and Strategic Development Plans | ||||
Cartesian Therapeutics | BUY $54→$49 | ― | -16.70% | Reiterated | Buy Rating Affirmed for Cartesian Therapeutics on Descartes-08's Promising Clinical Trial Results | ||||
Kyverna Therapeutics, Inc. | HOLD $8 | ― | -16.70% | Initiated | Hold Rating on Kyverna Therapeutics Amid Efficacy Concerns and Rising Competition in CAR-T Landscape | ||||
Assertio Therapeutics | BUY $4 | ― | -1.40% | Initiated | Assertio Holdings initiated with a Buy at H.C. Wainwright | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $115→$92 | ― | 5.40% | Reiterated | |||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $67 | ― | 9.40% | Reiterated | |||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $341→$325 | ― | 19.80% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $25→$28 | ― | 13.50% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $9 | ― | 11.30% | Upgraded | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $160→$248 | ― | 6.20% | Reiterated |